Caroline Kennedy
Physician Assistant · Atlanta, GANPI 1467181974
Payments from drug & device makers
Across 260 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$680
- Lilly USA, LLC$555
- GSK$457
- AstraZeneca$311
- Bayer$223
- plus $2K from 38 others
What the payments were for
- Food & beverage$6,022100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$242
- Kerendia$126
- Veozah$125
- QULIPTA$125
- MOUNJARO$122
- DEXCOM G7 GSS (161)$121
- VIBERZI$116
- GVOKE HYPOPEN$113
How this compares
$6,022 in reported general payments places this provider in the 90th percentile of 3,581 physician assistant providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 61 | $74,696 |
| FarxigaDapagliflozin Propanediol | 46 | $54,172 |
| JardianceEmpagliflozin | 34 | $42,547 |
| OzempicSemaglutide | 28 | $40,039 |
| XareltoRivaroxaban | 25 | $32,168 |
| LinzessLinaclotide | 21 | $21,797 |
| JanuviaSitagliptin Phosphate | 18 | $21,015 |
| MyrbetriqMirabegron | 12 | $13,315 |
| MounjaroTirzepatide | 11 | $13,082 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $9,795 |
| Repatha SureclickEvolocumab | 15 | $8,160 |
| Novolog FlexpenInsulin Aspart | 12 | $3,509 |
| Atorvastatin Calcium | 262 | $2,546 |
| Rosuvastatin Calcium | 208 | $2,424 |
| Nifedipine ErNifedipine | 81 | $1,899 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $40 | $74,69661 claims |
| AstraZenecaFarxiga | $311 | $54,17246 claims |
| Boehringer IngelheimJardiance | $143 | $42,54734 claims |
| Novo NordiskOzempic | $680 | $40,03928 claims |
| Johnson & JohnsonXarelto | $30 | $32,16825 claims |
| AbbVieLinzess, Synthroid | $1,301 | $22,65435 claims |
| MerckJanuvia | $63 | $21,01518 claims |
| Astellas Pharma US IncMyrbetriq | $189 | $13,31512 claims |
| Lilly USA, LLCMounjaro | $555 | $13,08211 claims |
| GSKTrelegy Ellipta | $457 | $9,79512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,581 physician assistant providers in Georgia.
Other physician assistant in Atlanta
- Jennifer CobbsAtlanta$1M
- Alison MoeAtlanta$410K
- Maggie SchreckAtlanta$389K
- Jaime AckermanAtlanta$84K
- Andrew GoodnerAtlanta$56K
- Tiffany LangemanAtlanta$53K
- Amy SimoneAtlanta$51K
- Rachel NeelyAtlanta$44K
- Jennifer YoungAtlanta$32K
- Kia CampbellAtlanta$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.